Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM-Allo.MSC in severe COVID-19
NCT04397796Phase 1Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BM-Allo.MSC with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events Within 30 Days of Randomization. Started Aug 2020; status: terminated.
02
Drugs
BM-Allo.MSC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04397796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397796.